FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Context Therapeutics Inc. reported that the FDA has granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer in patients who have received all standard therapies.
CTIM-76 is being studied in a Phase 1 clinical trial in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, assessing safety, tolerability, pharmacokinetics and anti-tumor activity. The company expects interim Phase 1a data for CTIM-76 in June 2026, highlighting a near-term clinical milestone for this program.
Positive
- FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer recognizes the program’s potential to address a serious unmet medical need and can provide access to expedited development and review tools.
- Defined near-term catalyst with interim Phase 1a data for CTIM-76 expected in June 2026, giving clearer visibility into upcoming clinical progress for the company’s lead T cell engaging bispecific antibody.
Negative
- None.
Insights
FDA Fast Track status for CTIM-76 accelerates development timelines and adds a defined clinical milestone in June 2026.
The FDA Fast Track designation for CTIM-76 signals that regulators see potential to address a serious unmet need in platinum-resistant ovarian cancer after standard therapies. Fast Track can provide more frequent FDA interactions and eligibility for expedited review pathways, which may streamline development.
CTIM-76 is already in a Phase 1 trial in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, focused on safety and early efficacy signals such as overall response rate and duration of response. The company plans to share interim Phase 1a data in June 2026, giving investors a concrete upcoming data catalyst tied directly to this designation.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Regulatory status: FDA Fast Track designation
Interim data timing: June 2026
Trial phase: Phase 1
+1 more
4 metrics
Regulatory status
FDA Fast Track designation
Granted to CTIM-76 for platinum-resistant ovarian cancer
Interim data timing
June 2026
Expected Phase 1a interim data for CTIM-76
Trial phase
Phase 1
Clinical trial of CTIM-76 in CLDN6-positive solid tumors
Clinical trial identifier
NCT06515613
CTIM-76 clinical trial listing on clinicaltrials.gov
Key Terms
Fast Track designation, T cell engaging bispecific antibody, platinum-resistant ovarian cancer, Phase 1 clinical trial, +1 more
5 terms
Fast Track designation regulatory
"the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to CTIM-76"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
T cell engaging bispecific antibody medical
"CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody"
platinum-resistant ovarian cancer medical
"for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients"
A form of ovarian cancer that stops responding to standard platinum-based chemotherapy, typically when the disease returns within about six months after treatment; think of it like a pest becoming resistant to a once-effective pesticide. It matters to investors because this resistance creates a large unmet medical need, shaping demand for new drugs, clinical trial strategies, regulatory priority and potential pricing — all of which can materially affect company value and market opportunity.
Phase 1 clinical trial medical
"Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
overall response rate medical
"anti-tumor activity by overall response rate, duration of response and disease control rate"
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2026
(Exact name of registrant as specified in its charter)
| (State of other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Title of each class | Trading Symbol | Name of exchange on which registered | ||||||||||||
$0.001 par value per share | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On April 2, 2026, Context Therapeutics Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to CTIM-76, the Company’s investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 8.01. Other Events.
On April 2, 2026, the Company issued a press release announcing that the FDA has granted Fast Track designation to CTIM-76, the Company’s investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by Context Therapeutics Inc., dated April 2, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: April 2, 2026 | Context Therapeutics Inc. | |||||||
| By: | /s/ Martin A. Lehr | |||||||
| Name: Martin A. Lehr | ||||||||
| Title: Chief Executive Officer | ||||||||
Exhibit 99.1
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC
CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026
PHILADELPHIA, PA— April 2, 2026 —Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients that have received all standard of care therapies.
Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate.
“We are pleased to receive Fast Track Designation for CTIM-76, which underscores its potential to improve the lives of patients with platinum-resistant ovarian cancer,” said Karen Chagin, M.D., Chief Medical Officer of Context. “This designation is an important step forward in our goal to quickly and efficiently advance CTIM-76 through clinical development and we look forward to sharing interim data for this program in June 2026.”
The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need.
About CTIM-76
CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on https://clinicaltrials.gov/.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE
Exhibit 99.1
bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company’s expectation to provide Phase 1a interim data for CTIM-76 in June 2026, (ii) the potential benefits, characteristics, safety and side effect profile of the Company’s product candidates, (iii) the likelihood data will support future development, and (iv) the likelihood of obtaining regulatory approval of the Company’s product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the Company therefore cannot assure the reader that its plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company’s expectation to provide Phase 1a interim data for CTIM-76 in June 2026, (ii) the potential benefits, characteristics, safety and side effect profile of the Company’s product candidates, (iii) the likelihood data will support future development, and (iv) the likelihood of obtaining regulatory approval of the Company’s product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the Company therefore cannot assure the reader that its plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com
IR@contexttherapeutics.com
FAQ
What did Context Therapeutics (CNTX) announce regarding CTIM-76?
Context Therapeutics announced that the FDA granted Fast Track designation to CTIM-76, its Claudin 6 x CD3 T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer after all standard therapies. This supports potentially faster development and review for this investigational therapy.
What is FDA Fast Track designation for CTIM-76 in CNTX’s 8-K?
Fast Track designation is an FDA program to expedite development and review of drugs that may treat serious conditions with unmet need. For CTIM-76, it acknowledges potential benefit in platinum-resistant ovarian cancer and can allow more frequent FDA interactions and eligibility for certain expedited review options.
Which patients are targeted by CTIM-76 in Context Therapeutics’ program?
CTIM-76 targets patients with platinum-resistant ovarian cancer who have already received all standard of care therapies. The ongoing Phase 1 trial also enrolls subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers to evaluate safety, tolerability and early anti-tumor activity.
What stage of clinical development is CTIM-76 for Context Therapeutics (CNTX)?
CTIM-76 is in a Phase 1 clinical trial evaluating safety and efficacy in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The study includes dose escalation and expansion, examining safety, tolerability, pharmacokinetics, overall response rate, duration of response and disease control rate.
When does Context Therapeutics expect interim CTIM-76 data?
Context Therapeutics expects to share interim Phase 1a data for CTIM-76 in June 2026. This interim readout should provide early insight into safety, tolerability, pharmacokinetics and anti-tumor activity, including measures such as overall response rate and disease control rate in CLDN6-positive solid tumors.
What cancer types could CTIM-76 potentially address for CNTX?
CTIM-76 targets CLDN6, which is enriched in several solid tumors, including ovarian, endometrial, lung, gastric and testicular cancers. The current Phase 1 trial focuses on CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, exploring safety and early signs of anti-tumor activity.
Filing Exhibits & Attachments
4 documents
Context Therapeutics Inc
NASDAQ:CNTX
CNTX Rankings
CNTX Latest News
CNTX Latest SEC Filings
Mar 23, 2026
[10-K] Context Therapeutics Inc. Files Annual Report